MGMT protein expression is a reliable predictive biomarker for temozolomide‐containing chemotherapy in osteosarcoma - Uchihara, Yoshinori; Umeda, Katsutsugu; Yamada, Yosuke; Ito, Hiroaki; Tasaka, Keiji; Isobe, Kiyotaka; Akazawa, Ryo; Kawabata, Naoko; Saida, Satoshi; Kato, Itaru; Hiramatsu, Hidefumi; Noguchi, Takashi; et al. (Cancer Science, 2024)
Keywords: biomarker; Bone cancer; Chemotherapy; Clinical outcomes; DNA methylation; DNA methyltransferase; Females; Genetic testing; Glioma; Immunohistochemistry; Lesions; Medical prognosis; Metastasis; Methylguanine; Multivariate analysis; O6-methylguanine-DNA methyltransferase; Original; ORIGINAL ARTICLE; Osteosarcoma; O‐6‐methylguanine DNA methyltransferase; Patients; Protein expression; Proteins; Radiation therapy; recurrence; Surgery; Temozolomide; Tumors; recurrence; temozolomide; O‐6‐methylguanine DNA methyltransferase; biomarker; osteosarcoma